Completed PHASE1 INTERVENTIONAL 1-arm NCT00408525

Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease

Efficacy of Donepezil in Normalizing Brain Activation Patterns in People Genetically at Risk for Alzheimer's Disease

Sponsor: Vanderbilt University

Interventions donepezil

Updated 6 times since 2017 Last updated: Feb 1, 2018 Started: Dec 31, 2006 Primary completion: Aug 24, 2012 Completion: Aug 24, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Alzheimer's Disease and is currently completed. Vanderbilt University leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Mar 2018 — Jun 2018 [monthly]

Completed PHASE1

Status: Unknown Status → Completed · Phase: PHASE1_PHASE2 → PHASE1

▶ Show 1 earlier version

Jan 2017 — Mar 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vanderbilt University

Data source: Vanderbilt University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nashville, United States